By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CSL Limited 

45 Poplar Road

Parkville  Victoria  3052  Australia
Phone: 61-3-9389-1911 Fax: 61-3-9389-1434



Company News
CSL Limited (CMXHF.PK) Launches AEGIS-I, A Phase 2b Clinical Study Of CSL112, A Novel Apolipoprotein A-I Infusion Therapy Designed To Rapidly Remove Cholesterol From Arteries And Stabilize Plaque 11/12/2014 7:14:14 AM
Novartis AG (NVS) Sells Flu Vaccine Business For $275 Million To CSL Limited (CMXHF.PK) 10/27/2014 5:50:08 AM
Apathy Sends Biotech Jobs Offshore, Says CSL Limited (CMXHF.PK) 8/18/2014 8:03:22 AM
ASLAN Pharmaceuticals Pte Ltd In-Licenses Novel Asthma Therapy From CSL Limited (CMXHF.PK) 5/13/2014 8:21:13 AM
CSL Limited (CMXHF.PK) Takes Unused Blood Components To Make Cholesterol Drug 11/20/2013 10:33:25 AM
CSL Limited (CMXHF.PK) and Plasma Protein Therapeutics Association Agree to Pay $64 Million to Settle Plasma-Derivative Protein Therapies Antitrust Case 10/11/2013 7:21:43 AM
CSL Behring Parent Company, CSL Limited (CMXHF.PK), Issues Fourth Corporate Responsibility Report 12/4/2012 9:00:45 AM
PharmaJet Enters into Strategic Collaboration With CSL Limited (CMXHF.PK) for Needle-Free Delivery of Influenza Vaccines 11/30/2012 11:47:50 AM
Novel Apolipoprotein A-I Therapy, CSL Limited (CMXHF.PK)112, May Represent New Option for Reducing Recurrent Heart Attack Risk, Early CSL Studies Show 11/5/2012 12:46:46 PM
CSL Limited (CMXHF.PK): Viral Component Likely Cause of Convulsions in Kids Given Fluvax 6/20/2012 7:12:50 AM